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Methoxetamine [2-(3-methoxyphenyl)-2-(ethylamino) cyclohexanone, MXE] is a 
arylcyclohexylamine derivative of ketamine (KET), which differs from the latter for the insertion, 
on the phenyl ring, of 3-methoxy and N-ethylamino groups in place of 2-chloro and N-methylamino 
groups respectively. The N-ethylamino group accounts for MXE increased potency and duration of 
action as compared to KET, whereas the 3-methoxy group is responsible for decreased analgesic 
and anesthetic properties. MXE is available in form of white powder, and it is assumed under 
different routes of administration, including nasal insufflations, oral consumption, sublingual or 
rectal administration, intramuscular (IM) or intravenous (IV) injections.  
Dosages can range from 20 to 100 mg for oral administration and from 10 up to 100 mg for IV and 
IM administrations. MXE mechanism of action and effects are believed to be mediated through a 
combination of N-methyl-D aspartate (NMDA) receptor antagonism, dopamine reuptake inhibition, 
and muscarinic cholinergic and serotonin (5-HT2) receptors agonism. Human cytochrome CYP2B6 
and CYP3A4 are believed to be involved in initial metabolic pathway, which ultimately leads to N-
desethyl(nor)methoxetamine, MXE main biologically active metabolite.   
According to consumers’ self-reported experiences, effects of MXE are similar to those of KET, 
except for longer duration and longer delay onset, which may lead to an increased risk of re-dose. 
MXE desired psychotropic effects include euphoria, increased empathy and social interactions, 
pleasant intensification of sensory experiences, dissociative experiences from physical body (i.e., 
M-Hole). At higher doses MXE can be responsible for particularly unpleasant effects such as near-
death experiences or marked alterations in consciousness, including catatonia, hallucinations, 
confusion, agitation, delirium, shift in perception of time and space. MXE intoxication may also 
cause neurological symptoms such as cerebral ataxia, dysarthria, nystagmus, and motor 
incoordination. In addition, MXE may induce sympathomimetic toxicity as evidenced by 
tachycardia and hypertension [1].  
Recent studies and reports confirmed MXE abuse liability as well as the risk of fatal intoxication 
when MXE is assumed at high doses or in combination with other substances [2]. Along with other 
novel psychoactive substances (NPSs), MXE has been recently classified as a scheduled I substance 
in the European Union and in other countries. Evidence supports the “psychotomimetic” properties 
of MXE which, possibly via NMDA receptor modulation, may elicit psychotic phenomena (e.g., 
alterations in perception, thinking, and feeling), as well as neurocognitive dysfunction [3]. 
 
 
 
 
Case Report 
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We report the case of a 23-year-old man, whose child development was apparently normal and his 
family history free from psychiatric disorders. He reported occasional consume of alcohol, 
cannabis, ketamine, and LSD during late adolescence. However, his past medical history was free 
from any major psychiatric disorder. One day his mother found him unconscious in his room. He 
was immediately brought to the Emergency Department (ED) where physical examination and 
laboratory analysis revealed a state of acute kidney (serum creatinine: 2.34 mg/dL; serum cystatin 
C: 1.42 mg/dL; Urea: 55.8 mg/dL; CPK 17.000 U/L) and respiratory failure (arterial PaO2: 52 
mmHg; arterial PaCO2: 50 mmHg). ECG also showed an incomplete right bundle branch block. 
Blood and urine samples were negative for ethanol, benzodiazepines, cannabinoids, cocaine, 
amphetamine, methadone, opioids, and tricyclic substances. He was firstly managed with 
supportive care, including tracheal intubation and mechanical ventilation. Symptoms resolved after 
two weeks of treatment with atenolol 100 mg/d, clonidine 150 mg/d, nitrosorbide 40 mg/d, and 
hemodialysis. A 10 mL serum (kept at – 20° C) sample collected at the ED was sent to the Pavia 
Poison Control Center which used gas chromatography-mass and liquid chromatography-tandem 
mass spectrometry techniques to identify possible NPs. MXE traces were confirmed within 
patient’s blood serum at a dosage of 0.29 μg/ml. Once patient’s medical conditions restored, he was 
transferred to a psychiatric residential treatment center. Here, he sufficiently dealt with daily 
activities and slightly conversed with other patients or staff members. A blunted affective 
responsiveness, including curbing of interests, diminished social drive and impoverished speech 
was noticed, without marked abnormalities of mental state or behavior. He also reported to 
continuously experience visual and auditory hallucinations as if during MXE “high”. He admitted to 
having IV injected himself an unspecified amount of MXE retrieved on internet, after his girlfriend 
revealed him she wanted to break up. He was administered a psychometric assessment, which 
indicated severe dissociative symptoms, including detachment from reality and absorption in 
imaginative thoughts, along with marked affective withdrawal and motivational anhedonia. The 
patient also underwent a neuropsychological evaluation, which revealed a mild impairment of 
verbal fluency, working memory and increased distractibility (Table 1). Clinical 
electroencephalography was normal. He was prescribed a magnetic resonance imaging (MRI) and a 
[18F]-fluorodeoxyglucose-Positron Emission Tomography integrated with computed tomography 
(18F-FDG PET/CT). Axial/sagittal T1-weigthed, axial FLAIR, and axial/coronal T2-weighted MRI 
images revealed no morphological or structural alterations within brain tissues and the whole 
ventricular system. 
 
Brain FDG distribution analysis of the PET/CT was performed by using the Scenium software 
(Siemens) which allows to compare FDG uptake of a single subject with a standardized database of 
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normal subjects. The scan showed a bilateral deficit of tracer uptake within Middle frontal gyrus 
(MFG), more evident in the right side (Figure 1). This was confirmed with the software analysis by 
a significant difference of the number of standard deviations (SDs) between the mean standardized 
uptake value (SUV) of the patient compared to normal subjects (-3.5 SD in the right side and -2.5 
SD in the left side). 
He was then prescribed aripiprazole 15 mg/d and N-acetylcysteine 2 g/d given the efficacy of the 
compounds in treating psychotic symptoms and substance-related withdrawal, partially via 
glutamate neurotransmission restoring [4-5]. Symptoms gradually improved within twelve weeks 
(Table 1). He was finally discharged with a DSM-5 diagnosis of Substance-Induced Psychotic 
Disorder.  
MXE mechanisms of neural toxicity have not yet been established in humans. Similar to other 
NMDA antagonists, MXE proved to affect emotional processing and working memory in rodent 
models possibly via increased phosphorylation of ribosomal proteins [6-7]. The present case-report 
documented a bilateral middle frontal gyrus (MFG) impairment, as revealed by 18F-FDG PET 
images, in MXE-induced psychotic disorder. The glutamate hypothesis suggests that hypofunction 
of NMDA receptors may account for the pathophysiology of psychotic disorders, given that NMDA 
antagonists mimic both positive and negative symptoms of disease as well as cognitive 
impairments. Along with other lateral prefrontal and parietal bilateral areas, MFG, of which 
dorsolateral prefrontal cortex (DLPFC) is part, constitute a central executive network (CEN), whose 
activity is critical to goal-oriented cognitive functions, including working memory and sustained 
attention. A decreased local resting state activity within CEN structures (e.g., DLPFC), has been 
supposed to mediate, in several psychiatric disorders, a shift from external, goal-oriented mental 
contents, to internal, self-directed thoughts. Such an imbalance between internal and external 
mental contents in awareness, may ultimately leads to several psychopathological symptoms, 
including rumination, social withdrawal and lack of motivation [8]. Moreover, lower metabolic 
rates in DLPFC, as revealed by PET studies, have been implicated in the pathophysiology of several 
clinical features among psychotic subjects, including negative symptomatology and impaired 
cognitive functioning [9]. MXE may thus share psychotomimetic properties of KET and other 
NMDA antagonists, which, partially through MFG impairment, may induce symptoms such as 
perceptual aberrations, working memory impairment, and emotional withdrawal that resemble early 
stages of schizophrenia [10]. 
NPSs acute intoxication has currently become a public health major concern, because of relatively 
easy accessibility to these compounds and difficulty in identifying them with routine laboratory 
techniques. Similarly, clinical features of NPSs intoxication are difficult to recognize and classify. 
This report highlights that MXE intoxication may produce severe brain damages even after a single 
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consumption. Therefore, patients should be carefully warned of the serious risks they incur when 
assuming NPSs.  
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Figure 1. Brain 18F-FDG PET/CT. A (series): multiple views of global FDG uptake parameterized with 
mean SUV difference from normal subject (Scenium analysis). B, C, D: respectively axial, coronal and 
sagittal view of PET scan where a bilateral lower FDG uptake is evident in MFG 
 
 
 
 
ASSESSMENT PATIENT SCORE 
ADMISSION                                DISCHARGE 
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PANSS 
Positive Symptoms 
Negative Symptoms 
General Psychopathology 
Total 
BNSS 
Anhedonia 
Distress 
Asociality  
Avolition 
Blunted Affect 
Quantity of Speech 
Total 
TEPS 
Anticipatory Pleasure 
Consummatory Pleasure 
Total 
DES-II 
Amnesia 
Depersonalization-Derealization 
Absorption 
Total 
MMSE 
TMT A 
Time 
Errors 
TMT B 
Time 
Errors 
DIGIT SPAN 
Forward 
Backward 
Total 
PVF 
 
 
12 
30 
32 
74 
 
13 
3 
7 
7 
11 
7 
48 
 
21 
26 
47 
 
10 
41.6 
35 
22.15 
28 
 
51 
1 
 
124 
0 
 
3 
4 
7 
32 
 
7 
20 
21 
48 
 
8 
2 
5 
5 
9 
6 
35 
 
17 
23 
40 
 
6 
17.14 
13.64 
11.79 
29 
 
35 
0 
 
92 
0 
 
5 
6 
11 
51 
Legend: BNSS, Brief Negative Symptoms Scale; DES-II, Dissociative Experience Scale; MMSE, Mini Mental State Examination; PANSS, Positive 
and Negative Syndrome Scale; PVF, Phonemic Verbal Fluency; TEPS, Temporary Experience Pleasure Scale; TMT, Trail Making Test. 
 
 
Table 1. Psychometric and neuropsychological evaluation. 
 
 
